Evidence map›Paper›PMID 32883310›Full record

ArticleRetrovirology2020

HLA-B*35 as a new marker for susceptibility to human T-cell lymphotropic virus type 1 (HTLV-1) Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) in patients living in Argentina.

Paula Benencio, Sindy A Fraile Gonzalez, Nicolás Ducasa, Kimberly Page, Carolina A Berini, Mirna M Biglione

Open access · goldAbstract read
In one paragraph

Article in Retrovirology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Paula BenencioCONICET- Universidad de Buenos Aires, Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Paraguay 2155, C1121ABG, Ciudad Autónoma de Buenos Aires, Argentina.
Sindy A Fraile GonzalezCONICET- Universidad de Buenos Aires, Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Paraguay 2155, C1121ABG, Ciudad Autónoma de Buenos Aires, Argentina.
Nicolás DucasaCONICET- Universidad de Buenos Aires, Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Paraguay 2155, C1121ABG, Ciudad Autónoma de Buenos Aires, Argentina.
Kimberly PageDepartment of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, USA.
Carolina A BeriniCONICET- Universidad de Buenos Aires, Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Paraguay 2155, C1121ABG, Ciudad Autónoma de Buenos Aires, Argentina. cberini@fmed.uba.ar.
Mirna M BiglioneCONICET- Universidad de Buenos Aires, Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Paraguay 2155, C1121ABG, Ciudad Autónoma de Buenos Aires, Argentina.
Instituto de Investigaciones Biomédicas en Retrovirus y Sida · ARConsejo Nacional de Investigaciones Científicas y Técnicas · ARUniversity of California, San Francisco · US

Funding

Int'l Traineeships in AIDS Prevention Studies (ITAPS)R25MH064712 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LINDAN, CHRISTINA P · 2002 to 2018
$3.4M
NIMH NIH HHS R25 MH064712
6 · The paper itself

Abstract

backgroundHuman T-cell lymphotropic virus type 1 (HTLV-1) is the etiological agent of HTLV associated myelopathy/ Tropical Spastic Paraparesis (HAM/TSP) and Adult T cell leukemia/lymphoma (ATLL), in around 2-5% of the infected individuals. Host genetic background might play a role in disease progression. Several previous studies across many countries report HLA haplotype to be one such factor. Here, we sequenced HLA-A, -B and -C of 66 individuals by Sequence-Based Typing (SBT), and compared the frequency of different alleles among ATLL patients, HAM/TSP patients, asymptomatic carriers and non-infected individuals living in Argentina.

resultsThe frequency of HLA-A, -B and -C alleles largely matched that of the general population in Argentina. We identified HLA-A*02, HLA-B*35 and HLA-C*07 as associated to protection from ATLL (p = 0.031), susceptibility to HAM/TSP (p < 0.001) and susceptibility to ATLL (p = 0.017), respectively. We also found a strong correlation between high proviral load (PVL) and disease (p = 0.008), but were unable to identify any particular allele associated with high or low PVL.

conclusionsWe have found HLA-A*02, HLA-B*35 and HLA-C*07 to be associated to protection from ATLL (HLA-A*02) and susceptibility to HAM/TSP (HLA-B*35) or to ATLL (HLA-C*07), respectively. Whereas HLA-A*02 protection from ATLL has already been extensively described in other regions of the world, this is the first report that links HLA-B*35 and an increased susceptibility to HAM/TSP. As for HLA-C*07 it has previously been associated to susceptibility to HAM/TSP in other countries but in our population it has been linked to ATLL.

Indexed as

AdolescentAdultAllelesArgentinaDisease ProgressionFemaleGenetic Association StudiesGenetic MarkersGenetic Predisposition to DiseaseHLA-A2 AntigenHLA-B35 AntigenHLA-C AntigensHTLV-I InfectionsHumansHuman T-lymphotropic virus 1Leukemia-Lymphoma, Adult T-CellGenetic MarkersHLA-A2 AntigenHLA-B35 AntigenHLA-C AntigensARGENTINAATLLHAM/TSPHLAHTLV-1PVL

Identifiers

PMID32883310
PMCPMC7469403
OpenAlexW3081824735

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.